nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—lung cancer—muscle cancer	0.609	1	CtDrD
Crizotinib—AURKA—Doxorubicin—muscle cancer	0.107	0.714	CbGbCtD
Crizotinib—ABCB1—Dactinomycin—muscle cancer	0.00755	0.0504	CbGbCtD
Crizotinib—CYP3A5—Vincristine—muscle cancer	0.00714	0.0477	CbGbCtD
Crizotinib—CYP3A5—Etoposide—muscle cancer	0.00655	0.0437	CbGbCtD
Crizotinib—ABCB1—Vincristine—muscle cancer	0.00465	0.031	CbGbCtD
Crizotinib—ABCB1—Etoposide—muscle cancer	0.00426	0.0284	CbGbCtD
Crizotinib—ABCB1—Doxorubicin—muscle cancer	0.00291	0.0194	CbGbCtD
Crizotinib—ABCB1—Methotrexate—muscle cancer	0.00281	0.0188	CbGbCtD
Crizotinib—CYP3A4—Vincristine—muscle cancer	0.00279	0.0186	CbGbCtD
Crizotinib—CYP3A4—Etoposide—muscle cancer	0.00255	0.017	CbGbCtD
Crizotinib—CYP3A4—Doxorubicin—muscle cancer	0.00174	0.0116	CbGbCtD
Crizotinib—Febrile neutropenia—Dactinomycin—muscle cancer	0.000859	0.0234	CcSEcCtD
Crizotinib—Febrile neutropenia—Vincristine—muscle cancer	0.000767	0.0209	CcSEcCtD
Crizotinib—Peripheral sensory neuropathy—Doxorubicin—muscle cancer	0.000678	0.0185	CcSEcCtD
Crizotinib—Hepatotoxicity—Dactinomycin—muscle cancer	0.000669	0.0183	CcSEcCtD
Crizotinib—Febrile neutropenia—Etoposide—muscle cancer	0.000621	0.017	CcSEcCtD
Crizotinib—Polyneuropathy—Doxorubicin—muscle cancer	0.000595	0.0162	CcSEcCtD
Crizotinib—CASK—Teniposide—Etoposide—muscle cancer	0.000573	0.197	CbGdCrCtD
Crizotinib—Interstitial lung disease—Etoposide—muscle cancer	0.000528	0.0144	CcSEcCtD
Crizotinib—Hepatotoxicity—Etoposide—muscle cancer	0.000484	0.0132	CcSEcCtD
Crizotinib—Gait disturbance—Vincristine—muscle cancer	0.000473	0.0129	CcSEcCtD
Crizotinib—Respiratory failure—Vincristine—muscle cancer	0.00047	0.0128	CcSEcCtD
Crizotinib—Dysaesthesia—Doxorubicin—muscle cancer	0.000448	0.0122	CcSEcCtD
Crizotinib—Sepsis—Dactinomycin—muscle cancer	0.000448	0.0122	CcSEcCtD
Crizotinib—Neuropathy—Vincristine—muscle cancer	0.000433	0.0118	CcSEcCtD
Crizotinib—Hepatic failure—Dactinomycin—muscle cancer	0.000417	0.0114	CcSEcCtD
Crizotinib—Lymphopenia—Doxorubicin—muscle cancer	0.000379	0.0103	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Etoposide—muscle cancer	0.000374	0.0102	CcSEcCtD
Crizotinib—Hepatic failure—Vincristine—muscle cancer	0.000373	0.0102	CcSEcCtD
Crizotinib—Febrile neutropenia—Methotrexate—muscle cancer	0.000372	0.0102	CcSEcCtD
Crizotinib—Neuropathy—Etoposide—muscle cancer	0.000351	0.00959	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.000338	0.00922	CcSEcCtD
Crizotinib—Hypophosphataemia—Doxorubicin—muscle cancer	0.000334	0.00911	CcSEcCtD
Crizotinib—Generalised oedema—Doxorubicin—muscle cancer	0.000326	0.0089	CcSEcCtD
Crizotinib—Sepsis—Etoposide—muscle cancer	0.000324	0.00886	CcSEcCtD
Crizotinib—Burning sensation—Methotrexate—muscle cancer	0.000322	0.0088	CcSEcCtD
Crizotinib—Febrile neutropenia—Doxorubicin—muscle cancer	0.000322	0.0088	CcSEcCtD
Crizotinib—Transaminases increased—Doxorubicin—muscle cancer	0.000319	0.0087	CcSEcCtD
Crizotinib—Interstitial lung disease—Methotrexate—muscle cancer	0.000316	0.00864	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Etoposide—muscle cancer	0.000312	0.00852	CcSEcCtD
Crizotinib—Neutropenia—Dactinomycin—muscle cancer	0.000303	0.00828	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.000302	0.00824	CcSEcCtD
Crizotinib—Muscular weakness—Vincristine—muscle cancer	0.000295	0.00807	CcSEcCtD
Crizotinib—Pneumonia—Dactinomycin—muscle cancer	0.000291	0.00794	CcSEcCtD
Crizotinib—Hepatotoxicity—Methotrexate—muscle cancer	0.00029	0.00792	CcSEcCtD
Crizotinib—Abscess—Methotrexate—muscle cancer	0.000283	0.00773	CcSEcCtD
Crizotinib—PLK4—Teniposide—Etoposide—muscle cancer	0.000283	0.0974	CbGdCrCtD
Crizotinib—Neuralgia—Doxorubicin—muscle cancer	0.000279	0.00762	CcSEcCtD
Crizotinib—Burning sensation—Doxorubicin—muscle cancer	0.000279	0.00762	CcSEcCtD
Crizotinib—STK3—tendon—muscle cancer	0.000271	0.00292	CbGeAlD
Crizotinib—SRC—embryo—muscle cancer	0.000271	0.00292	CbGeAlD
Crizotinib—Neutropenia—Vincristine—muscle cancer	0.000271	0.00739	CcSEcCtD
Crizotinib—IRAK1—smooth muscle tissue—muscle cancer	0.00027	0.0029	CbGeAlD
Crizotinib—FER—vagina—muscle cancer	0.000269	0.0029	CbGeAlD
Crizotinib—EPHA5—vagina—muscle cancer	0.000269	0.0029	CbGeAlD
Crizotinib—JAK3—head—muscle cancer	0.000268	0.00288	CbGeAlD
Crizotinib—EPHA6—head—muscle cancer	0.000268	0.00288	CbGeAlD
Crizotinib—TNK1—vagina—muscle cancer	0.000266	0.00287	CbGeAlD
Crizotinib—DCLK1—head—muscle cancer	0.000266	0.00287	CbGeAlD
Crizotinib—MAP4K2—bone marrow—muscle cancer	0.000266	0.00286	CbGeAlD
Crizotinib—PTK2—renal system—muscle cancer	0.000265	0.00285	CbGeAlD
Crizotinib—TBK1—renal system—muscle cancer	0.000265	0.00285	CbGeAlD
Crizotinib—RPS6KB1—smooth muscle tissue—muscle cancer	0.000265	0.00285	CbGeAlD
Crizotinib—AURKA—tendon—muscle cancer	0.000264	0.00284	CbGeAlD
Crizotinib—MAP4K1—vagina—muscle cancer	0.000264	0.00284	CbGeAlD
Crizotinib—TYK2—renal system—muscle cancer	0.000263	0.00283	CbGeAlD
Crizotinib—STK4—head—muscle cancer	0.000263	0.00283	CbGeAlD
Crizotinib—AXL—smooth muscle tissue—muscle cancer	0.000262	0.00282	CbGeAlD
Crizotinib—TESK1—tendon—muscle cancer	0.000262	0.00282	CbGeAlD
Crizotinib—Weight decreased—Vincristine—muscle cancer	0.000262	0.00715	CcSEcCtD
Crizotinib—IGF1R—Idarubicin—Doxorubicin—muscle cancer	0.00026	0.0895	CbGdCrCtD
Crizotinib—Pneumonia—Vincristine—muscle cancer	0.00026	0.00709	CcSEcCtD
Crizotinib—JAK3—testis—muscle cancer	0.000259	0.00279	CbGeAlD
Crizotinib—EPHA6—testis—muscle cancer	0.000259	0.00279	CbGeAlD
Crizotinib—IGF1R—vagina—muscle cancer	0.000259	0.00278	CbGeAlD
Crizotinib—DCLK1—testis—muscle cancer	0.000257	0.00277	CbGeAlD
Crizotinib—AURKA—bone marrow—muscle cancer	0.000256	0.00275	CbGeAlD
Crizotinib—PLK4—testis—muscle cancer	0.000256	0.00275	CbGeAlD
Crizotinib—RIPK2—cardiac atrium—muscle cancer	0.000256	0.00275	CbGeAlD
Crizotinib—MAP4K2—vagina—muscle cancer	0.000255	0.00274	CbGeAlD
Crizotinib—RPS6KB1—renal system—muscle cancer	0.000255	0.00274	CbGeAlD
Crizotinib—MERTK—tendon—muscle cancer	0.000255	0.00274	CbGeAlD
Crizotinib—STK4—testis—muscle cancer	0.000254	0.00274	CbGeAlD
Crizotinib—Neuropathy peripheral—Vincristine—muscle cancer	0.000253	0.00691	CcSEcCtD
Crizotinib—STK3—vagina—muscle cancer	0.000251	0.00271	CbGeAlD
Crizotinib—EPHB4—smooth muscle tissue—muscle cancer	0.00025	0.0027	CbGeAlD
Crizotinib—JAK2—smooth muscle tissue—muscle cancer	0.000249	0.00268	CbGeAlD
Crizotinib—ALK—head—muscle cancer	0.000249	0.00268	CbGeAlD
Crizotinib—FER—head—muscle cancer	0.000249	0.00268	CbGeAlD
Crizotinib—EPHA5—head—muscle cancer	0.000249	0.00268	CbGeAlD
Crizotinib—TYRO3—head—muscle cancer	0.000249	0.00268	CbGeAlD
Crizotinib—LYN—head—muscle cancer	0.000247	0.00266	CbGeAlD
Crizotinib—EPHA4—cardiac atrium—muscle cancer	0.000247	0.00266	CbGeAlD
Crizotinib—MERTK—bone marrow—muscle cancer	0.000247	0.00266	CbGeAlD
Crizotinib—ACVR1—tendon—muscle cancer	0.000247	0.00265	CbGeAlD
Crizotinib—MAP3K12—tendon—muscle cancer	0.000247	0.00265	CbGeAlD
Crizotinib—AURKA—vagina—muscle cancer	0.000245	0.00264	CbGeAlD
Crizotinib—Abscess—Doxorubicin—muscle cancer	0.000245	0.00669	CcSEcCtD
Crizotinib—MAP3K19—head—muscle cancer	0.000244	0.00262	CbGeAlD
Crizotinib—BMPR1B—head—muscle cancer	0.000244	0.00262	CbGeAlD
Crizotinib—CSF1R—embryo—muscle cancer	0.000243	0.00262	CbGeAlD
Crizotinib—TESK1—vagina—muscle cancer	0.000243	0.00262	CbGeAlD
Crizotinib—STK35—tendon—muscle cancer	0.000242	0.0026	CbGeAlD
Crizotinib—EPHB4—renal system—muscle cancer	0.000241	0.0026	CbGeAlD
Crizotinib—NUAK2—bone marrow—muscle cancer	0.000241	0.00259	CbGeAlD
Crizotinib—ALK—testis—muscle cancer	0.00024	0.00259	CbGeAlD
Crizotinib—FER—testis—muscle cancer	0.00024	0.00259	CbGeAlD
Crizotinib—TYRO3—testis—muscle cancer	0.00024	0.00259	CbGeAlD
Crizotinib—MAP4K5—smooth muscle tissue—muscle cancer	0.00024	0.00258	CbGeAlD
Crizotinib—TEK—smooth muscle tissue—muscle cancer	0.00024	0.00258	CbGeAlD
Crizotinib—JAK2—renal system—muscle cancer	0.000239	0.00258	CbGeAlD
Crizotinib—Alanine aminotransferase increased—Etoposide—muscle cancer	0.000239	0.00654	CcSEcCtD
Crizotinib—FLT3—bone marrow—muscle cancer	0.000239	0.00257	CbGeAlD
Crizotinib—ACVR1—bone marrow—muscle cancer	0.000239	0.00257	CbGeAlD
Crizotinib—TNK2—head—muscle cancer	0.000239	0.00257	CbGeAlD
Crizotinib—IGF1R—head—muscle cancer	0.000239	0.00257	CbGeAlD
Crizotinib—TNK1—testis—muscle cancer	0.000238	0.00256	CbGeAlD
Crizotinib—TBK1—cardiac atrium—muscle cancer	0.000237	0.00255	CbGeAlD
Crizotinib—MERTK—vagina—muscle cancer	0.000236	0.00255	CbGeAlD
Crizotinib—TYK2—cardiac atrium—muscle cancer	0.000236	0.00254	CbGeAlD
Crizotinib—ABL2—tendon—muscle cancer	0.000235	0.00253	CbGeAlD
Crizotinib—MAP4K1—testis—muscle cancer	0.000235	0.00253	CbGeAlD
Crizotinib—BMPR1B—testis—muscle cancer	0.000235	0.00253	CbGeAlD
Crizotinib—MAP3K19—testis—muscle cancer	0.000235	0.00253	CbGeAlD
Crizotinib—BMP2K—tendon—muscle cancer	0.000233	0.0025	CbGeAlD
Crizotinib—STK3—head—muscle cancer	0.000232	0.0025	CbGeAlD
Crizotinib—TIE1—head—muscle cancer	0.000232	0.0025	CbGeAlD
Crizotinib—LIMK2—vagina—muscle cancer	0.000231	0.00249	CbGeAlD
Crizotinib—TEK—renal system—muscle cancer	0.000231	0.00248	CbGeAlD
Crizotinib—TNK2—testis—muscle cancer	0.000231	0.00248	CbGeAlD
Crizotinib—IGF1R—testis—muscle cancer	0.000231	0.00248	CbGeAlD
Crizotinib—Hypoaesthesia—Vincristine—muscle cancer	0.000231	0.0063	CcSEcCtD
Crizotinib—NUAK2—vagina—muscle cancer	0.00023	0.00248	CbGeAlD
Crizotinib—Urinary tract disorder—Vincristine—muscle cancer	0.000229	0.00625	CcSEcCtD
Crizotinib—MAP3K12—vagina—muscle cancer	0.000229	0.00246	CbGeAlD
Crizotinib—ACVR1—vagina—muscle cancer	0.000229	0.00246	CbGeAlD
Crizotinib—RPS6KB1—cardiac atrium—muscle cancer	0.000228	0.00246	CbGeAlD
Crizotinib—Respiratory failure—Methotrexate—muscle cancer	0.000228	0.00623	CcSEcCtD
Crizotinib—MAP4K2—testis—muscle cancer	0.000227	0.00245	CbGeAlD
Crizotinib—Urethral disorder—Vincristine—muscle cancer	0.000227	0.0062	CcSEcCtD
Crizotinib—AURKA—head—muscle cancer	0.000226	0.00244	CbGeAlD
Crizotinib—AXL—cardiac atrium—muscle cancer	0.000226	0.00243	CbGeAlD
Crizotinib—BMP2K—bone marrow—muscle cancer	0.000225	0.00242	CbGeAlD
Crizotinib—PTK2B—tendon—muscle cancer	0.000225	0.00242	CbGeAlD
Crizotinib—TESK1—head—muscle cancer	0.000225	0.00242	CbGeAlD
Crizotinib—STK3—testis—muscle cancer	0.000224	0.00242	CbGeAlD
Crizotinib—TIE1—testis—muscle cancer	0.000224	0.00242	CbGeAlD
Crizotinib—STK35—vagina—muscle cancer	0.000224	0.00241	CbGeAlD
Crizotinib—Pulmonary embolism—Methotrexate—muscle cancer	0.000224	0.00612	CcSEcCtD
Crizotinib—RIPK2—tendon—muscle cancer	0.000223	0.0024	CbGeAlD
Crizotinib—AURKA—Teniposide—Etoposide—muscle cancer	0.000222	0.0763	CbGdCrCtD
Crizotinib—YES1—smooth muscle tissue—muscle cancer	0.000221	0.00238	CbGeAlD
Crizotinib—Neutropenia—Etoposide—muscle cancer	0.000219	0.00599	CcSEcCtD
Crizotinib—AURKA—testis—muscle cancer	0.000219	0.00235	CbGeAlD
Crizotinib—ABL2—vagina—muscle cancer	0.000218	0.00235	CbGeAlD
Crizotinib—MERTK—head—muscle cancer	0.000218	0.00235	CbGeAlD
Crizotinib—PTK2B—bone marrow—muscle cancer	0.000218	0.00234	CbGeAlD
Crizotinib—SLK—cardiac atrium—muscle cancer	0.000217	0.00234	CbGeAlD
Crizotinib—TESK1—testis—muscle cancer	0.000217	0.00234	CbGeAlD
Crizotinib—EPHB4—cardiac atrium—muscle cancer	0.000216	0.00232	CbGeAlD
Crizotinib—BMP2K—vagina—muscle cancer	0.000216	0.00232	CbGeAlD
Crizotinib—RIPK2—bone marrow—muscle cancer	0.000216	0.00232	CbGeAlD
Crizotinib—EPHA4—tendon—muscle cancer	0.000215	0.00232	CbGeAlD
Crizotinib—Cardiac disorder—Vincristine—muscle cancer	0.000215	0.00587	CcSEcCtD
Crizotinib—JAK2—cardiac atrium—muscle cancer	0.000214	0.00231	CbGeAlD
Crizotinib—LIMK2—head—muscle cancer	0.000214	0.0023	CbGeAlD
Crizotinib—YES1—renal system—muscle cancer	0.000213	0.00229	CbGeAlD
Crizotinib—SRC—smooth muscle tissue—muscle cancer	0.000213	0.00229	CbGeAlD
Crizotinib—EPHA2—cardiac atrium—muscle cancer	0.000212	0.00228	CbGeAlD
Crizotinib—MAP3K12—head—muscle cancer	0.000211	0.00228	CbGeAlD
Crizotinib—ACVR1—head—muscle cancer	0.000211	0.00228	CbGeAlD
Crizotinib—STK10—renal system—muscle cancer	0.000211	0.00227	CbGeAlD
Crizotinib—MERTK—testis—muscle cancer	0.000211	0.00227	CbGeAlD
Crizotinib—TAOK3—renal system—muscle cancer	0.00021	0.00226	CbGeAlD
Crizotinib—Pneumonia—Etoposide—muscle cancer	0.00021	0.00574	CcSEcCtD
Crizotinib—CDK7—Daunorubicin—Doxorubicin—muscle cancer	0.00021	0.0721	CbGdCrCtD
Crizotinib—CDK7—Epirubicin—Doxorubicin—muscle cancer	0.00021	0.0721	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Doxorubicin—muscle cancer	0.00021	0.0721	CbGdCrCtD
Crizotinib—Infestation NOS—Etoposide—muscle cancer	0.000209	0.00571	CcSEcCtD
Crizotinib—Infestation—Etoposide—muscle cancer	0.000209	0.00571	CcSEcCtD
Crizotinib—Mediastinal disorder—Vincristine—muscle cancer	0.000209	0.0057	CcSEcCtD
Crizotinib—Anaemia—Dactinomycin—muscle cancer	0.000209	0.0057	CcSEcCtD
Crizotinib—PTK2B—vagina—muscle cancer	0.000208	0.00224	CbGeAlD
Crizotinib—STK35—head—muscle cancer	0.000207	0.00223	CbGeAlD
Crizotinib—PTK2—tendon—muscle cancer	0.000207	0.00223	CbGeAlD
Crizotinib—TBK1—tendon—muscle cancer	0.000207	0.00223	CbGeAlD
Crizotinib—RIPK2—vagina—muscle cancer	0.000207	0.00223	CbGeAlD
Crizotinib—MAP3K3—cardiac atrium—muscle cancer	0.000207	0.00222	CbGeAlD
Crizotinib—MAP4K5—cardiac atrium—muscle cancer	0.000207	0.00222	CbGeAlD
Crizotinib—TEK—cardiac atrium—muscle cancer	0.000207	0.00222	CbGeAlD
Crizotinib—LIMK2—testis—muscle cancer	0.000206	0.00222	CbGeAlD
Crizotinib—NUAK2—testis—muscle cancer	0.000206	0.00221	CbGeAlD
Crizotinib—TYK2—tendon—muscle cancer	0.000205	0.00221	CbGeAlD
Crizotinib—SRC—renal system—muscle cancer	0.000205	0.00221	CbGeAlD
Crizotinib—Neuropathy peripheral—Etoposide—muscle cancer	0.000205	0.0056	CcSEcCtD
Crizotinib—MAP3K2—bone marrow—muscle cancer	0.000205	0.0022	CbGeAlD
Crizotinib—MAP3K12—testis—muscle cancer	0.000204	0.0022	CbGeAlD
Crizotinib—ACVR1—testis—muscle cancer	0.000204	0.0022	CbGeAlD
Crizotinib—FLT3—testis—muscle cancer	0.000204	0.0022	CbGeAlD
Crizotinib—IRAK1—tendon—muscle cancer	0.000203	0.00218	CbGeAlD
Crizotinib—Leukopenia—Dactinomycin—muscle cancer	0.000202	0.00552	CcSEcCtD
Crizotinib—TBK1—bone marrow—muscle cancer	0.0002	0.00216	CbGeAlD
Crizotinib—STK35—testis—muscle cancer	0.0002	0.00215	CbGeAlD
Crizotinib—EPHA4—vagina—muscle cancer	0.0002	0.00215	CbGeAlD
Crizotinib—BMP2K—head—muscle cancer	0.000199	0.00215	CbGeAlD
Crizotinib—TYK2—bone marrow—muscle cancer	0.000199	0.00214	CbGeAlD
Crizotinib—RPS6KB1—tendon—muscle cancer	0.000199	0.00214	CbGeAlD
Crizotinib—Gait disturbance—Doxorubicin—muscle cancer	0.000199	0.00543	CcSEcCtD
Crizotinib—Hepatobiliary disease—Etoposide—muscle cancer	0.000198	0.0054	CcSEcCtD
Crizotinib—FGR—tendon—muscle cancer	0.000198	0.00213	CbGeAlD
Crizotinib—EPHB6—cardiac atrium—muscle cancer	0.000197	0.00213	CbGeAlD
Crizotinib—AXL—tendon—muscle cancer	0.000197	0.00212	CbGeAlD
Crizotinib—IRAK1—bone marrow—muscle cancer	0.000196	0.00211	CbGeAlD
Crizotinib—ABL2—testis—muscle cancer	0.000195	0.0021	CbGeAlD
Crizotinib—Sepsis—Methotrexate—muscle cancer	0.000194	0.00531	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Doxorubicin—muscle cancer	0.000194	0.0053	CcSEcCtD
Crizotinib—Pulmonary embolism—Doxorubicin—muscle cancer	0.000194	0.0053	CcSEcCtD
Crizotinib—RPS6KB1—bone marrow—muscle cancer	0.000193	0.00207	CbGeAlD
Crizotinib—BMP2K—testis—muscle cancer	0.000193	0.00207	CbGeAlD
Crizotinib—PTK2B—head—muscle cancer	0.000193	0.00207	CbGeAlD
Crizotinib—ABL1—embryo—muscle cancer	0.000192	0.00207	CbGeAlD
Crizotinib—TBK1—vagina—muscle cancer	0.000192	0.00207	CbGeAlD
Crizotinib—PTK2—vagina—muscle cancer	0.000192	0.00207	CbGeAlD
Crizotinib—FGR—bone marrow—muscle cancer	0.000192	0.00206	CbGeAlD
Crizotinib—LCK—bone marrow—muscle cancer	0.000192	0.00206	CbGeAlD
Crizotinib—CSF1R—smooth muscle tissue—muscle cancer	0.000191	0.00206	CbGeAlD
Crizotinib—RIPK2—head—muscle cancer	0.000191	0.00206	CbGeAlD
Crizotinib—YES1—cardiac atrium—muscle cancer	0.000191	0.00205	CbGeAlD
Crizotinib—TYK2—vagina—muscle cancer	0.000191	0.00205	CbGeAlD
Crizotinib—SLK—tendon—muscle cancer	0.00019	0.00204	CbGeAlD
Crizotinib—TAOK3—cardiac atrium—muscle cancer	0.000188	0.00203	CbGeAlD
Crizotinib—EPHB4—tendon—muscle cancer	0.000188	0.00203	CbGeAlD
Crizotinib—JAK2—tendon—muscle cancer	0.000187	0.00201	CbGeAlD
Crizotinib—Hypoaesthesia—Etoposide—muscle cancer	0.000187	0.0051	CcSEcCtD
Crizotinib—Anaemia—Vincristine—muscle cancer	0.000186	0.00509	CcSEcCtD
Crizotinib—PTK2B—testis—muscle cancer	0.000186	0.002	CbGeAlD
Crizotinib—Urinary tract disorder—Etoposide—muscle cancer	0.000185	0.00506	CcSEcCtD
Crizotinib—EPHA2—tendon—muscle cancer	0.000185	0.00199	CbGeAlD
Crizotinib—RPS6KB1—vagina—muscle cancer	0.000185	0.00199	CbGeAlD
Crizotinib—EPHA4—head—muscle cancer	0.000185	0.00199	CbGeAlD
Crizotinib—RIPK2—testis—muscle cancer	0.000184	0.00199	CbGeAlD
Crizotinib—Oedema—Dactinomycin—muscle cancer	0.000184	0.00503	CcSEcCtD
Crizotinib—Fluid retention—Doxorubicin—muscle cancer	0.000184	0.00503	CcSEcCtD
Crizotinib—Urethral disorder—Etoposide—muscle cancer	0.000184	0.00503	CcSEcCtD
Crizotinib—SLK—bone marrow—muscle cancer	0.000184	0.00198	CbGeAlD
Crizotinib—SRC—cardiac atrium—muscle cancer	0.000184	0.00198	CbGeAlD
Crizotinib—LCK—vagina—muscle cancer	0.000183	0.00198	CbGeAlD
Crizotinib—FGR—vagina—muscle cancer	0.000183	0.00198	CbGeAlD
Crizotinib—Infection—Dactinomycin—muscle cancer	0.000183	0.005	CcSEcCtD
Crizotinib—AXL—vagina—muscle cancer	0.000183	0.00197	CbGeAlD
Crizotinib—EPHB4—bone marrow—muscle cancer	0.000182	0.00196	CbGeAlD
Crizotinib—Neuropathy—Doxorubicin—muscle cancer	0.000182	0.00497	CcSEcCtD
Crizotinib—JAK2—bone marrow—muscle cancer	0.000181	0.00195	CbGeAlD
Crizotinib—MAP3K2—head—muscle cancer	0.000181	0.00195	CbGeAlD
Crizotinib—Hepatic failure—Methotrexate—muscle cancer	0.000181	0.00494	CcSEcCtD
Crizotinib—Leukopenia—Vincristine—muscle cancer	0.000181	0.00493	CcSEcCtD
Crizotinib—MAP4K5—tendon—muscle cancer	0.00018	0.00194	CbGeAlD
Crizotinib—MAP3K3—tendon—muscle cancer	0.00018	0.00194	CbGeAlD
Crizotinib—TEK—tendon—muscle cancer	0.00018	0.00194	CbGeAlD
Crizotinib—EPHA4—testis—muscle cancer	0.000178	0.00192	CbGeAlD
Crizotinib—PTK2—head—muscle cancer	0.000177	0.00191	CbGeAlD
Crizotinib—TBK1—head—muscle cancer	0.000177	0.00191	CbGeAlD
Crizotinib—TYK2—head—muscle cancer	0.000176	0.0019	CbGeAlD
Crizotinib—SLK—vagina—muscle cancer	0.000176	0.00189	CbGeAlD
Crizotinib—Eye disorder—Etoposide—muscle cancer	0.000175	0.00479	CcSEcCtD
Crizotinib—MAP3K2—testis—muscle cancer	0.000175	0.00188	CbGeAlD
Crizotinib—EPHB4—vagina—muscle cancer	0.000175	0.00188	CbGeAlD
Crizotinib—MAP4K5—bone marrow—muscle cancer	0.000174	0.00188	CbGeAlD
Crizotinib—MAP3K3—bone marrow—muscle cancer	0.000174	0.00188	CbGeAlD
Crizotinib—Cardiac disorder—Etoposide—muscle cancer	0.000174	0.00476	CcSEcCtD
Crizotinib—JAK2—vagina—muscle cancer	0.000173	0.00187	CbGeAlD
Crizotinib—EPHB6—tendon—muscle cancer	0.000172	0.00185	CbGeAlD
Crizotinib—Visual disturbance—Methotrexate—muscle cancer	0.000172	0.00468	CcSEcCtD
Crizotinib—EPHA2—vagina—muscle cancer	0.000171	0.00184	CbGeAlD
Crizotinib—TBK1—testis—muscle cancer	0.000171	0.00184	CbGeAlD
Crizotinib—PTK2—testis—muscle cancer	0.000171	0.00184	CbGeAlD
Crizotinib—RPS6KB1—head—muscle cancer	0.000171	0.00184	CbGeAlD
Crizotinib—TYK2—testis—muscle cancer	0.00017	0.00183	CbGeAlD
Crizotinib—FGR—head—muscle cancer	0.000169	0.00182	CbGeAlD
Crizotinib—Mediastinal disorder—Etoposide—muscle cancer	0.000169	0.00462	CcSEcCtD
Crizotinib—AXL—head—muscle cancer	0.000169	0.00182	CbGeAlD
Crizotinib—Sepsis—Doxorubicin—muscle cancer	0.000168	0.00459	CcSEcCtD
Crizotinib—IRAK1—testis—muscle cancer	0.000168	0.00181	CbGeAlD
Crizotinib—MAP3K3—vagina—muscle cancer	0.000167	0.0018	CbGeAlD
Crizotinib—MAP4K5—vagina—muscle cancer	0.000167	0.0018	CbGeAlD
Crizotinib—YES1—tendon—muscle cancer	0.000166	0.00179	CbGeAlD
Crizotinib—STK10—tendon—muscle cancer	0.000165	0.00177	CbGeAlD
Crizotinib—CSF1R—cardiac atrium—muscle cancer	0.000165	0.00177	CbGeAlD
Crizotinib—RPS6KB1—testis—muscle cancer	0.000165	0.00177	CbGeAlD
Crizotinib—Oedema—Vincristine—muscle cancer	0.000165	0.0045	CcSEcCtD
Crizotinib—TAOK3—tendon—muscle cancer	0.000164	0.00177	CbGeAlD
Crizotinib—LCK—testis—muscle cancer	0.000164	0.00176	CbGeAlD
Crizotinib—FGR—testis—muscle cancer	0.000164	0.00176	CbGeAlD
Crizotinib—Infection—Vincristine—muscle cancer	0.000164	0.00447	CcSEcCtD
Crizotinib—AXL—testis—muscle cancer	0.000163	0.00176	CbGeAlD
Crizotinib—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	0.000162	0.00442	CcSEcCtD
Crizotinib—Nervous system disorder—Vincristine—muscle cancer	0.000161	0.00441	CcSEcCtD
Crizotinib—YES1—bone marrow—muscle cancer	0.000161	0.00173	CbGeAlD
Crizotinib—Hepatic function abnormal—Doxorubicin—muscle cancer	0.000161	0.0044	CcSEcCtD
Crizotinib—Decreased appetite—Dactinomycin—muscle cancer	0.00016	0.00437	CcSEcCtD
Crizotinib—JAK2—head—muscle cancer	0.00016	0.00172	CbGeAlD
Crizotinib—Dysgeusia—Etoposide—muscle cancer	0.00016	0.00437	CcSEcCtD
Crizotinib—EPHB6—vagina—muscle cancer	0.00016	0.00172	CbGeAlD
Crizotinib—STK10—bone marrow—muscle cancer	0.00016	0.00172	CbGeAlD
Crizotinib—TAOK3—bone marrow—muscle cancer	0.000159	0.00171	CbGeAlD
Crizotinib—Fatigue—Dactinomycin—muscle cancer	0.000159	0.00434	CcSEcCtD
Crizotinib—EPHA2—head—muscle cancer	0.000158	0.0017	CbGeAlD
Crizotinib—SLK—testis—muscle cancer	0.000157	0.00169	CbGeAlD
Crizotinib—Hepatic failure—Doxorubicin—muscle cancer	0.000157	0.00428	CcSEcCtD
Crizotinib—EPHB4—testis—muscle cancer	0.000156	0.00168	CbGeAlD
Crizotinib—JAK2—testis—muscle cancer	0.000155	0.00167	CbGeAlD
Crizotinib—MAP4K5—head—muscle cancer	0.000154	0.00166	CbGeAlD
Crizotinib—TEK—head—muscle cancer	0.000154	0.00166	CbGeAlD
Crizotinib—MAP3K3—head—muscle cancer	0.000154	0.00166	CbGeAlD
Crizotinib—YES1—vagina—muscle cancer	0.000154	0.00166	CbGeAlD
Crizotinib—STK10—vagina—muscle cancer	0.000153	0.00165	CbGeAlD
Crizotinib—EPHA2—testis—muscle cancer	0.000153	0.00165	CbGeAlD
Crizotinib—TAOK3—vagina—muscle cancer	0.000152	0.00164	CbGeAlD
Crizotinib—ABL1—smooth muscle tissue—muscle cancer	0.000151	0.00163	CbGeAlD
Crizotinib—Anaemia—Etoposide—muscle cancer	0.000151	0.00412	CcSEcCtD
Crizotinib—MAP3K3—testis—muscle cancer	0.000149	0.00161	CbGeAlD
Crizotinib—TEK—testis—muscle cancer	0.000149	0.00161	CbGeAlD
Crizotinib—MAP4K5—testis—muscle cancer	0.000149	0.00161	CbGeAlD
Crizotinib—Paraesthesia—Vincristine—muscle cancer	0.000148	0.00404	CcSEcCtD
Crizotinib—EPHB6—head—muscle cancer	0.000148	0.00159	CbGeAlD
Crizotinib—Leukopenia—Etoposide—muscle cancer	0.000146	0.00399	CcSEcCtD
Crizotinib—Body temperature increased—Dactinomycin—muscle cancer	0.000146	0.00398	CcSEcCtD
Crizotinib—ABL1—renal system—muscle cancer	0.000145	0.00157	CbGeAlD
Crizotinib—CSF1R—tendon—muscle cancer	0.000144	0.00155	CbGeAlD
Crizotinib—Loss of consciousness—Etoposide—muscle cancer	0.000144	0.00392	CcSEcCtD
Crizotinib—Decreased appetite—Vincristine—muscle cancer	0.000143	0.00391	CcSEcCtD
Crizotinib—YES1—head—muscle cancer	0.000143	0.00153	CbGeAlD
Crizotinib—EPHB6—testis—muscle cancer	0.000143	0.00153	CbGeAlD
Crizotinib—Gastrointestinal disorder—Vincristine—muscle cancer	0.000142	0.00388	CcSEcCtD
Crizotinib—Fatigue—Vincristine—muscle cancer	0.000142	0.00388	CcSEcCtD
Crizotinib—STK10—head—muscle cancer	0.000141	0.00152	CbGeAlD
Crizotinib—Constipation—Vincristine—muscle cancer	0.000141	0.00385	CcSEcCtD
Crizotinib—TAOK3—head—muscle cancer	0.000141	0.00152	CbGeAlD
Crizotinib—Diplopia—Doxorubicin—muscle cancer	0.000141	0.00384	CcSEcCtD
Crizotinib—CSF1R—bone marrow—muscle cancer	0.000139	0.0015	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000138	0.00377	CcSEcCtD
Crizotinib—YES1—testis—muscle cancer	0.000138	0.00148	CbGeAlD
Crizotinib—SRC—head—muscle cancer	0.000137	0.00148	CbGeAlD
Crizotinib—PLK4—Idarubicin—Doxorubicin—muscle cancer	0.000137	0.047	CbGdCrCtD
Crizotinib—PLK4—Epirubicin—Doxorubicin—muscle cancer	0.000137	0.047	CbGdCrCtD
Crizotinib—STK10—testis—muscle cancer	0.000136	0.00147	CbGeAlD
Crizotinib—TAOK3—testis—muscle cancer	0.000136	0.00146	CbGeAlD
Crizotinib—Face oedema—Doxorubicin—muscle cancer	0.000136	0.00371	CcSEcCtD
Crizotinib—CSF1R—vagina—muscle cancer	0.000133	0.00144	CbGeAlD
Crizotinib—SRC—testis—muscle cancer	0.000133	0.00143	CbGeAlD
Crizotinib—Infection—Etoposide—muscle cancer	0.000132	0.00362	CcSEcCtD
Crizotinib—Asthenia—Dactinomycin—muscle cancer	0.000132	0.00361	CcSEcCtD
Crizotinib—Neutropenia—Methotrexate—muscle cancer	0.000131	0.00359	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000131	0.00357	CcSEcCtD
Crizotinib—ABL1—cardiac atrium—muscle cancer	0.00013	0.0014	CbGeAlD
Crizotinib—Body temperature increased—Vincristine—muscle cancer	0.00013	0.00355	CcSEcCtD
Crizotinib—Skin disorder—Etoposide—muscle cancer	0.00013	0.00354	CcSEcCtD
Crizotinib—Hypokalaemia—Doxorubicin—muscle cancer	0.000128	0.0035	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000127	0.00346	CcSEcCtD
Crizotinib—Diarrhoea—Dactinomycin—muscle cancer	0.000126	0.00344	CcSEcCtD
Crizotinib—Pneumonia—Methotrexate—muscle cancer	0.000126	0.00344	CcSEcCtD
Crizotinib—Infestation NOS—Methotrexate—muscle cancer	0.000125	0.00342	CcSEcCtD
Crizotinib—Infestation—Methotrexate—muscle cancer	0.000125	0.00342	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000124	0.00339	CcSEcCtD
Crizotinib—Muscular weakness—Doxorubicin—muscle cancer	0.000124	0.00339	CcSEcCtD
Crizotinib—CSF1R—head—muscle cancer	0.000123	0.00133	CbGeAlD
Crizotinib—Paraesthesia—Etoposide—muscle cancer	0.00012	0.00327	CcSEcCtD
Crizotinib—CSF1R—testis—muscle cancer	0.000119	0.00128	CbGeAlD
Crizotinib—Dyspnoea—Etoposide—muscle cancer	0.000119	0.00325	CcSEcCtD
Crizotinib—Hepatobiliary disease—Methotrexate—muscle cancer	0.000118	0.00324	CcSEcCtD
Crizotinib—Asthenia—Vincristine—muscle cancer	0.000118	0.00323	CcSEcCtD
Crizotinib—Vomiting—Dactinomycin—muscle cancer	0.000117	0.0032	CcSEcCtD
Crizotinib—Rash—Dactinomycin—muscle cancer	0.000116	0.00317	CcSEcCtD
Crizotinib—Decreased appetite—Etoposide—muscle cancer	0.000116	0.00317	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Etoposide—muscle cancer	0.000115	0.00314	CcSEcCtD
Crizotinib—Fatigue—Etoposide—muscle cancer	0.000115	0.00314	CcSEcCtD
Crizotinib—ABL1—Daunorubicin—Doxorubicin—muscle cancer	0.000115	0.0395	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Doxorubicin—muscle cancer	0.000115	0.0395	CbGdCrCtD
Crizotinib—ABL1—Epirubicin—Doxorubicin—muscle cancer	0.000115	0.0395	CbGdCrCtD
Crizotinib—Constipation—Etoposide—muscle cancer	0.000114	0.00311	CcSEcCtD
Crizotinib—Neutropenia—Doxorubicin—muscle cancer	0.000114	0.00311	CcSEcCtD
Crizotinib—ABL1—tendon—muscle cancer	0.000114	0.00122	CbGeAlD
Crizotinib—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000113	0.00309	CcSEcCtD
Crizotinib—Diarrhoea—Vincristine—muscle cancer	0.000113	0.00308	CcSEcCtD
Crizotinib—Urinary tract disorder—Methotrexate—muscle cancer	0.000111	0.00303	CcSEcCtD
Crizotinib—Urethral disorder—Methotrexate—muscle cancer	0.00011	0.00301	CcSEcCtD
Crizotinib—Weight decreased—Doxorubicin—muscle cancer	0.00011	0.00301	CcSEcCtD
Crizotinib—ABL1—bone marrow—muscle cancer	0.00011	0.00118	CbGeAlD
Crizotinib—Nausea—Dactinomycin—muscle cancer	0.000109	0.00299	CcSEcCtD
Crizotinib—Pneumonia—Doxorubicin—muscle cancer	0.000109	0.00298	CcSEcCtD
Crizotinib—Dizziness—Vincristine—muscle cancer	0.000109	0.00297	CcSEcCtD
Crizotinib—Infestation NOS—Doxorubicin—muscle cancer	0.000108	0.00296	CcSEcCtD
Crizotinib—Infestation—Doxorubicin—muscle cancer	0.000108	0.00296	CcSEcCtD
Crizotinib—Visual impairment—Methotrexate—muscle cancer	0.000108	0.00296	CcSEcCtD
Crizotinib—AURKA—Epirubicin—Doxorubicin—muscle cancer	0.000107	0.0368	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Doxorubicin—muscle cancer	0.000107	0.0368	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Doxorubicin—muscle cancer	0.000107	0.0368	CbGdCrCtD
Crizotinib—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000106	0.0029	CcSEcCtD
Crizotinib—Body temperature increased—Etoposide—muscle cancer	0.000105	0.00288	CcSEcCtD
Crizotinib—ABL1—vagina—muscle cancer	0.000105	0.00113	CbGeAlD
Crizotinib—Eye disorder—Methotrexate—muscle cancer	0.000105	0.00287	CcSEcCtD
Crizotinib—Vomiting—Vincristine—muscle cancer	0.000105	0.00286	CcSEcCtD
Crizotinib—Cardiac disorder—Methotrexate—muscle cancer	0.000104	0.00285	CcSEcCtD
Crizotinib—Rash—Vincristine—muscle cancer	0.000104	0.00284	CcSEcCtD
Crizotinib—Dermatitis—Vincristine—muscle cancer	0.000104	0.00283	CcSEcCtD
Crizotinib—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000103	0.0028	CcSEcCtD
Crizotinib—Mediastinal disorder—Methotrexate—muscle cancer	0.000101	0.00277	CcSEcCtD
Crizotinib—Bradycardia—Doxorubicin—muscle cancer	9.91e-05	0.00271	CcSEcCtD
Crizotinib—Malnutrition—Methotrexate—muscle cancer	9.79e-05	0.00267	CcSEcCtD
Crizotinib—Nausea—Vincristine—muscle cancer	9.78e-05	0.00267	CcSEcCtD
Crizotinib—ABL1—head—muscle cancer	9.73e-05	0.00105	CbGeAlD
Crizotinib—Hypoaesthesia—Doxorubicin—muscle cancer	9.69e-05	0.00265	CcSEcCtD
Crizotinib—Urinary tract disorder—Doxorubicin—muscle cancer	9.61e-05	0.00263	CcSEcCtD
Crizotinib—Oedema peripheral—Doxorubicin—muscle cancer	9.59e-05	0.00262	CcSEcCtD
Crizotinib—Dysgeusia—Methotrexate—muscle cancer	9.58e-05	0.00262	CcSEcCtD
Crizotinib—Asthenia—Etoposide—muscle cancer	9.57e-05	0.00261	CcSEcCtD
Crizotinib—Urethral disorder—Doxorubicin—muscle cancer	9.54e-05	0.00261	CcSEcCtD
Crizotinib—ABL1—testis—muscle cancer	9.4e-05	0.00101	CbGeAlD
Crizotinib—Visual impairment—Doxorubicin—muscle cancer	9.38e-05	0.00256	CcSEcCtD
Crizotinib—Vision blurred—Methotrexate—muscle cancer	9.22e-05	0.00252	CcSEcCtD
Crizotinib—Diarrhoea—Etoposide—muscle cancer	9.12e-05	0.00249	CcSEcCtD
Crizotinib—Eye disorder—Doxorubicin—muscle cancer	9.1e-05	0.00248	CcSEcCtD
Crizotinib—Anaemia—Methotrexate—muscle cancer	9.05e-05	0.00247	CcSEcCtD
Crizotinib—Cardiac disorder—Doxorubicin—muscle cancer	9.04e-05	0.00247	CcSEcCtD
Crizotinib—Dizziness—Etoposide—muscle cancer	8.82e-05	0.00241	CcSEcCtD
Crizotinib—Mediastinal disorder—Doxorubicin—muscle cancer	8.77e-05	0.0024	CcSEcCtD
Crizotinib—Leukopenia—Methotrexate—muscle cancer	8.76e-05	0.00239	CcSEcCtD
Crizotinib—Arrhythmia—Doxorubicin—muscle cancer	8.7e-05	0.00238	CcSEcCtD
Crizotinib—CYP3A5—renal system—muscle cancer	8.52e-05	0.000917	CbGeAlD
Crizotinib—Vomiting—Etoposide—muscle cancer	8.48e-05	0.00232	CcSEcCtD
Crizotinib—Malnutrition—Doxorubicin—muscle cancer	8.48e-05	0.00231	CcSEcCtD
Crizotinib—Rash—Etoposide—muscle cancer	8.41e-05	0.0023	CcSEcCtD
Crizotinib—Dermatitis—Etoposide—muscle cancer	8.4e-05	0.00229	CcSEcCtD
Crizotinib—Dysgeusia—Doxorubicin—muscle cancer	8.3e-05	0.00227	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	8.28e-05	0.00226	CcSEcCtD
Crizotinib—Vision blurred—Doxorubicin—muscle cancer	7.99e-05	0.00218	CcSEcCtD
Crizotinib—Infection—Methotrexate—muscle cancer	7.94e-05	0.00217	CcSEcCtD
Crizotinib—Nausea—Etoposide—muscle cancer	7.92e-05	0.00216	CcSEcCtD
Crizotinib—Nervous system disorder—Methotrexate—muscle cancer	7.83e-05	0.00214	CcSEcCtD
Crizotinib—Anaemia—Doxorubicin—muscle cancer	7.83e-05	0.00214	CcSEcCtD
Crizotinib—Skin disorder—Methotrexate—muscle cancer	7.76e-05	0.00212	CcSEcCtD
Crizotinib—Syncope—Doxorubicin—muscle cancer	7.6e-05	0.00208	CcSEcCtD
Crizotinib—Leukopenia—Doxorubicin—muscle cancer	7.59e-05	0.00207	CcSEcCtD
Crizotinib—Loss of consciousness—Doxorubicin—muscle cancer	7.45e-05	0.00203	CcSEcCtD
Crizotinib—Paraesthesia—Methotrexate—muscle cancer	7.17e-05	0.00196	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	7.17e-05	0.00196	CcSEcCtD
Crizotinib—Dyspnoea—Methotrexate—muscle cancer	7.12e-05	0.00195	CcSEcCtD
Crizotinib—Dyspepsia—Methotrexate—muscle cancer	7.03e-05	0.00192	CcSEcCtD
Crizotinib—Decreased appetite—Methotrexate—muscle cancer	6.94e-05	0.0019	CcSEcCtD
Crizotinib—Oedema—Doxorubicin—muscle cancer	6.92e-05	0.00189	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Methotrexate—muscle cancer	6.9e-05	0.00188	CcSEcCtD
Crizotinib—Fatigue—Methotrexate—muscle cancer	6.89e-05	0.00188	CcSEcCtD
Crizotinib—Infection—Doxorubicin—muscle cancer	6.87e-05	0.00188	CcSEcCtD
Crizotinib—Shock—Doxorubicin—muscle cancer	6.81e-05	0.00186	CcSEcCtD
Crizotinib—Nervous system disorder—Doxorubicin—muscle cancer	6.78e-05	0.00185	CcSEcCtD
Crizotinib—Skin disorder—Doxorubicin—muscle cancer	6.72e-05	0.00183	CcSEcCtD
Crizotinib—CYP3A4—renal system—muscle cancer	6.39e-05	0.000688	CbGeAlD
Crizotinib—Body temperature increased—Methotrexate—muscle cancer	6.31e-05	0.00172	CcSEcCtD
Crizotinib—Paraesthesia—Doxorubicin—muscle cancer	6.21e-05	0.0017	CcSEcCtD
Crizotinib—CYP3A5—vagina—muscle cancer	6.17e-05	0.000664	CbGeAlD
Crizotinib—Dyspnoea—Doxorubicin—muscle cancer	6.17e-05	0.00168	CcSEcCtD
Crizotinib—Dyspepsia—Doxorubicin—muscle cancer	6.09e-05	0.00166	CcSEcCtD
Crizotinib—Decreased appetite—Doxorubicin—muscle cancer	6.01e-05	0.00164	CcSEcCtD
Crizotinib—ABCB1—embryo—muscle cancer	5.98e-05	0.000643	CbGeAlD
Crizotinib—Gastrointestinal disorder—Doxorubicin—muscle cancer	5.97e-05	0.00163	CcSEcCtD
Crizotinib—Fatigue—Doxorubicin—muscle cancer	5.96e-05	0.00163	CcSEcCtD
Crizotinib—Constipation—Doxorubicin—muscle cancer	5.92e-05	0.00162	CcSEcCtD
Crizotinib—Asthenia—Methotrexate—muscle cancer	5.73e-05	0.00157	CcSEcCtD
Crizotinib—Body temperature increased—Doxorubicin—muscle cancer	5.47e-05	0.00149	CcSEcCtD
Crizotinib—Diarrhoea—Methotrexate—muscle cancer	5.47e-05	0.00149	CcSEcCtD
Crizotinib—Dizziness—Methotrexate—muscle cancer	5.28e-05	0.00144	CcSEcCtD
Crizotinib—Vomiting—Methotrexate—muscle cancer	5.08e-05	0.00139	CcSEcCtD
Crizotinib—Rash—Methotrexate—muscle cancer	5.04e-05	0.00138	CcSEcCtD
Crizotinib—Dermatitis—Methotrexate—muscle cancer	5.03e-05	0.00137	CcSEcCtD
Crizotinib—Asthenia—Doxorubicin—muscle cancer	4.96e-05	0.00136	CcSEcCtD
Crizotinib—Nausea—Methotrexate—muscle cancer	4.74e-05	0.0013	CcSEcCtD
Crizotinib—Diarrhoea—Doxorubicin—muscle cancer	4.73e-05	0.00129	CcSEcCtD
Crizotinib—Dizziness—Doxorubicin—muscle cancer	4.57e-05	0.00125	CcSEcCtD
Crizotinib—ABCB1—renal system—muscle cancer	4.52e-05	0.000487	CbGeAlD
Crizotinib—Vomiting—Doxorubicin—muscle cancer	4.4e-05	0.0012	CcSEcCtD
Crizotinib—Rash—Doxorubicin—muscle cancer	4.36e-05	0.00119	CcSEcCtD
Crizotinib—Dermatitis—Doxorubicin—muscle cancer	4.36e-05	0.00119	CcSEcCtD
Crizotinib—Nausea—Doxorubicin—muscle cancer	4.11e-05	0.00112	CcSEcCtD
Crizotinib—ABCB1—bone marrow—muscle cancer	3.42e-05	0.000368	CbGeAlD
Crizotinib—ABCB1—vagina—muscle cancer	3.28e-05	0.000353	CbGeAlD
Crizotinib—ABCB1—head—muscle cancer	3.03e-05	0.000326	CbGeAlD
Crizotinib—ABCB1—testis—muscle cancer	2.92e-05	0.000315	CbGeAlD
Crizotinib—SRC—Signaling by NGF—MDM2—muscle cancer	8.78e-06	8.06e-05	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—MDM2—muscle cancer	8.78e-06	8.06e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—KIT—muscle cancer	8.76e-06	8.05e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—HMGA1—muscle cancer	8.73e-06	8.02e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—KIT—muscle cancer	8.72e-06	8.01e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—KIT—muscle cancer	8.71e-06	8e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—KIT—muscle cancer	8.68e-06	7.97e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PTCH1—muscle cancer	8.67e-06	7.96e-05	CbGpPWpGaD
Crizotinib—TBK1—Immune System—MDM2—muscle cancer	8.64e-06	7.93e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—KIT—muscle cancer	8.56e-06	7.86e-05	CbGpPWpGaD
Crizotinib—JAK3—Hemostasis—TP53—muscle cancer	8.55e-06	7.85e-05	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—MDM2—muscle cancer	8.52e-06	7.82e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—FOXO1—muscle cancer	8.52e-06	7.82e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—KIT—muscle cancer	8.51e-06	7.81e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—FOXO4—muscle cancer	8.49e-06	7.79e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—KIT—muscle cancer	8.48e-06	7.79e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—FOXO1—muscle cancer	8.42e-06	7.73e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PTCH1—muscle cancer	8.42e-06	7.73e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—ENO2—muscle cancer	8.42e-06	7.73e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—KIT—muscle cancer	8.41e-06	7.73e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—FOXO1—muscle cancer	8.34e-06	7.66e-05	CbGpPWpGaD
Crizotinib—LYN—Axon guidance—VEGFA—muscle cancer	8.31e-06	7.63e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—MDM2—muscle cancer	8.28e-06	7.61e-05	CbGpPWpGaD
Crizotinib—ABL1—Axon guidance—VEGFA—muscle cancer	8.27e-06	7.6e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—FOXO1—muscle cancer	8.27e-06	7.59e-05	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—TP53—muscle cancer	8.21e-06	7.54e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—KIT—muscle cancer	8.2e-06	7.53e-05	CbGpPWpGaD
Crizotinib—SRC—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	8.19e-06	7.52e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IGF2—muscle cancer	8.15e-06	7.49e-05	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—VEGFA—muscle cancer	8.07e-06	7.41e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IGF2—muscle cancer	8.04e-06	7.38e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—FOXO1—muscle cancer	8.01e-06	7.36e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—FOXO4—muscle cancer	7.97e-06	7.32e-05	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—VEGFA—muscle cancer	7.96e-06	7.31e-05	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—VEGFA—muscle cancer	7.91e-06	7.27e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—FOXO4—muscle cancer	7.86e-06	7.22e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—FOXO4—muscle cancer	7.83e-06	7.19e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CNR1—muscle cancer	7.82e-06	7.19e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—MDM2—muscle cancer	7.81e-06	7.18e-05	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—VEGFA—muscle cancer	7.8e-06	7.17e-05	CbGpPWpGaD
Crizotinib—JAK2—Axon guidance—VEGFA—muscle cancer	7.78e-06	7.14e-05	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—VEGFA—muscle cancer	7.74e-06	7.11e-05	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—VEGFA—muscle cancer	7.74e-06	7.11e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—MDM2—muscle cancer	7.73e-06	7.1e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CNR1—muscle cancer	7.72e-06	7.09e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IGF2—muscle cancer	7.69e-06	7.06e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—HMGA1—muscle cancer	7.65e-06	7.03e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—FOXO1—muscle cancer	7.63e-06	7.01e-05	CbGpPWpGaD
Crizotinib—CDK7—Cell Cycle—TP53—muscle cancer	7.54e-06	6.92e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—FOXO1—muscle cancer	7.5e-06	6.89e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—FOXO4—muscle cancer	7.46e-06	6.85e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IGF2—muscle cancer	7.46e-06	6.85e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—ENO2—muscle cancer	7.45e-06	6.84e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—FOXO4—muscle cancer	7.43e-06	6.83e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—FOXO1—muscle cancer	7.39e-06	6.79e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—VEGFA—muscle cancer	7.34e-06	6.74e-05	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—VEGFA—muscle cancer	7.33e-06	6.73e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CNR1—muscle cancer	7.32e-06	6.72e-05	CbGpPWpGaD
Crizotinib—FGR—Hemostasis—TP53—muscle cancer	7.31e-06	6.71e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—FOXO4—muscle cancer	7.24e-06	6.65e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—KIT—muscle cancer	7.18e-06	6.59e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	7.17e-06	6.59e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—FH—muscle cancer	7.17e-06	6.58e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CNR1—muscle cancer	7.11e-06	6.53e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—FOXO1—muscle cancer	7.08e-06	6.5e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—MDM2—muscle cancer	6.99e-06	6.42e-05	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—TP53—muscle cancer	6.98e-06	6.41e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—MDM2—muscle cancer	6.96e-06	6.4e-05	CbGpPWpGaD
Crizotinib—SRC—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	6.96e-06	6.39e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—KIT—muscle cancer	6.94e-06	6.37e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	6.91e-06	6.35e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—MDM2—muscle cancer	6.9e-06	6.34e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—KIT—muscle cancer	6.9e-06	6.33e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—MDM2—muscle cancer	6.87e-06	6.31e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—MDM2—muscle cancer	6.86e-06	6.3e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—FOXO1—muscle cancer	6.86e-06	6.3e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—FOXO4—muscle cancer	6.86e-06	6.3e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—KIT—muscle cancer	6.84e-06	6.28e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—MDM2—muscle cancer	6.84e-06	6.28e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PTCH1—muscle cancer	6.82e-06	6.26e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—HMGA1—muscle cancer	6.77e-06	6.22e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—MDM2—muscle cancer	6.74e-06	6.19e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—VEGFA—muscle cancer	6.71e-06	6.16e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—MDM2—muscle cancer	6.7e-06	6.15e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—FOXO1—muscle cancer	6.7e-06	6.15e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—MDM2—muscle cancer	6.68e-06	6.13e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—FOXO1—muscle cancer	6.67e-06	6.12e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—MDM2—muscle cancer	6.63e-06	6.08e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—FOXO4—muscle cancer	6.58e-06	6.04e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—PTGS2—muscle cancer	6.5e-06	5.97e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—KIT—muscle cancer	6.49e-06	5.96e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—MDM2—muscle cancer	6.46e-06	5.93e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—KIT—muscle cancer	6.41e-06	5.89e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IGF2—muscle cancer	6.4e-06	5.88e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PTCH1—muscle cancer	6.38e-06	5.86e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—KIT—muscle cancer	6.36e-06	5.84e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IGF2—muscle cancer	6.31e-06	5.79e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—KIT—muscle cancer	6.3e-06	5.79e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—FOXO1—muscle cancer	6.27e-06	5.76e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—KIT—muscle cancer	6.1e-06	5.61e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—FOXO4—muscle cancer	6.07e-06	5.58e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—VEGFA—muscle cancer	6.03e-06	5.54e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IGF2—muscle cancer	5.98e-06	5.5e-05	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—TP53—muscle cancer	5.98e-06	5.49e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—VEGFA—muscle cancer	5.93e-06	5.45e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—VEGFA—muscle cancer	5.9e-06	5.42e-05	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—TP53—muscle cancer	5.9e-06	5.42e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—FOXO1—muscle cancer	5.89e-06	5.41e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—VEGFA—muscle cancer	5.87e-06	5.39e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—FOXO4—muscle cancer	5.86e-06	5.38e-05	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—TP53—muscle cancer	5.85e-06	5.37e-05	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—TP53—muscle cancer	5.85e-06	5.37e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—VEGFA—muscle cancer	5.82e-06	5.34e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—KIT—muscle cancer	5.82e-06	5.34e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IGF2—muscle cancer	5.81e-06	5.34e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—FOXO1—muscle cancer	5.81e-06	5.33e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—VEGFA—muscle cancer	5.79e-06	5.32e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—FOXO1—muscle cancer	5.79e-06	5.31e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CNR1—muscle cancer	5.75e-06	5.28e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—KIT—muscle cancer	5.72e-06	5.25e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—MDM2—muscle cancer	5.66e-06	5.19e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—KIT—muscle cancer	5.63e-06	5.17e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTCH1—muscle cancer	5.59e-06	5.13e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—VEGFA—muscle cancer	5.55e-06	5.1e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—TP53—muscle cancer	5.55e-06	5.09e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—FOXO1—muscle cancer	5.51e-06	5.06e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—FOXO1—muscle cancer	5.49e-06	5.04e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FOXO4—muscle cancer	5.49e-06	5.04e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—MDM2—muscle cancer	5.46e-06	5.02e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	5.45e-06	5e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—VEGFA—muscle cancer	5.45e-06	5e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—MDM2—muscle cancer	5.43e-06	4.99e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—KIT—muscle cancer	5.39e-06	4.95e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—MDM2—muscle cancer	5.39e-06	4.95e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CNR1—muscle cancer	5.38e-06	4.95e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MED12—muscle cancer	5.37e-06	4.93e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—FOXO1—muscle cancer	5.35e-06	4.91e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—VEGFA—muscle cancer	5.31e-06	4.87e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—KIT—muscle cancer	5.23e-06	4.8e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—VEGFA—muscle cancer	5.19e-06	4.77e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—MDM2—muscle cancer	5.11e-06	4.69e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—KIT—muscle cancer	5.1e-06	4.69e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—KIT—muscle cancer	5.08e-06	4.66e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—TP53—muscle cancer	5.07e-06	4.66e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—FOXO1—muscle cancer	5.07e-06	4.65e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MDM2—muscle cancer	5.05e-06	4.64e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—MDM2—muscle cancer	5.01e-06	4.6e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—MDM2—muscle cancer	4.96e-06	4.56e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTCH1—muscle cancer	4.95e-06	4.54e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ENO2—muscle cancer	4.89e-06	4.49e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—FOXO1—muscle cancer	4.86e-06	4.46e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—MDM2—muscle cancer	4.81e-06	4.42e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FOXO4—muscle cancer	4.8e-06	4.41e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KIT—muscle cancer	4.77e-06	4.39e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—VEGFA—muscle cancer	4.77e-06	4.38e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CNR1—muscle cancer	4.72e-06	4.33e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IGF2—muscle cancer	4.7e-06	4.32e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—MDM2—muscle cancer	4.58e-06	4.21e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MDM2—muscle cancer	4.5e-06	4.13e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—FOXO1—muscle cancer	4.49e-06	4.12e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KIT—muscle cancer	4.49e-06	4.12e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MDM2—muscle cancer	4.44e-06	4.08e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—TP53—muscle cancer	4.43e-06	4.07e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KIT—muscle cancer	4.42e-06	4.06e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—PTGS2—muscle cancer	4.42e-06	4.06e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—FH—muscle cancer	4.42e-06	4.06e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—KIT—muscle cancer	4.41e-06	4.05e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IGF2—muscle cancer	4.4e-06	4.04e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TP53—muscle cancer	4.4e-06	4.04e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TP53—muscle cancer	4.38e-06	4.02e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—FOXO1—muscle cancer	4.33e-06	3.98e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—VEGFA—muscle cancer	4.3e-06	3.95e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FOXO4—muscle cancer	4.25e-06	3.91e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MDM2—muscle cancer	4.25e-06	3.9e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—VEGFA—muscle cancer	4.22e-06	3.88e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KIT—muscle cancer	4.2e-06	3.85e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—KIT—muscle cancer	4.18e-06	3.84e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CNR1—muscle cancer	4.18e-06	3.83e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MDM2—muscle cancer	4.12e-06	3.78e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	4.12e-06	3.78e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TP53—muscle cancer	4.11e-06	3.78e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KIT—muscle cancer	4.07e-06	3.74e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FOXO1—muscle cancer	4.05e-06	3.72e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MED12—muscle cancer	4.05e-06	3.72e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—MDM2—muscle cancer	4.02e-06	3.69e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TP53—muscle cancer	4.01e-06	3.68e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—MDM2—muscle cancer	4e-06	3.67e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TP53—muscle cancer	3.92e-06	3.6e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—KIT—muscle cancer	3.86e-06	3.55e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IGF2—muscle cancer	3.86e-06	3.54e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—VEGFA—muscle cancer	3.84e-06	3.52e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—MDM2—muscle cancer	3.76e-06	3.45e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—KIT—muscle cancer	3.7e-06	3.4e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ENO2—muscle cancer	3.69e-06	3.39e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—muscle cancer	3.6e-06	3.31e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FOXO1—muscle cancer	3.55e-06	3.26e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MDM2—muscle cancer	3.53e-06	3.24e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MDM2—muscle cancer	3.48e-06	3.2e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—MDM2—muscle cancer	3.47e-06	3.19e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—VEGFA—muscle cancer	3.42e-06	3.14e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—KIT—muscle cancer	3.42e-06	3.14e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF2—muscle cancer	3.41e-06	3.14e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—VEGFA—muscle cancer	3.37e-06	3.09e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—PTGS2—muscle cancer	3.35e-06	3.07e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MDM2—muscle cancer	3.3e-06	3.03e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KIT—muscle cancer	3.3e-06	3.03e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—MDM2—muscle cancer	3.29e-06	3.02e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—VEGFA—muscle cancer	3.22e-06	2.96e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MDM2—muscle cancer	3.21e-06	2.95e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—muscle cancer	3.19e-06	2.93e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FOXO1—muscle cancer	3.14e-06	2.89e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—VEGFA—muscle cancer	3.13e-06	2.87e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KIT—muscle cancer	3.09e-06	2.84e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—MDM2—muscle cancer	3.04e-06	2.79e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—PTGS2—muscle cancer	2.93e-06	2.69e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—MDM2—muscle cancer	2.92e-06	2.68e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—muscle cancer	2.9e-06	2.66e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KIT—muscle cancer	2.7e-06	2.48e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—MDM2—muscle cancer	2.69e-06	2.47e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—muscle cancer	2.68e-06	2.46e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—muscle cancer	2.65e-06	2.43e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MDM2—muscle cancer	2.6e-06	2.39e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—muscle cancer	2.6e-06	2.38e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—muscle cancer	2.58e-06	2.37e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—muscle cancer	2.55e-06	2.34e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—muscle cancer	2.51e-06	2.3e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MED12—muscle cancer	2.49e-06	2.29e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—muscle cancer	2.44e-06	2.24e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—muscle cancer	2.44e-06	2.24e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MDM2—muscle cancer	2.43e-06	2.23e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KIT—muscle cancer	2.39e-06	2.2e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—muscle cancer	2.36e-06	2.17e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ENO2—muscle cancer	2.27e-06	2.09e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MDM2—muscle cancer	2.13e-06	1.96e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—muscle cancer	2.03e-06	1.86e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—muscle cancer	2e-06	1.84e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—muscle cancer	1.97e-06	1.81e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—muscle cancer	1.9e-06	1.74e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MDM2—muscle cancer	1.89e-06	1.73e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—muscle cancer	1.85e-06	1.7e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—muscle cancer	1.84e-06	1.69e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—muscle cancer	1.7e-06	1.57e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—muscle cancer	1.62e-06	1.49e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—muscle cancer	1.49e-06	1.37e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—muscle cancer	1.43e-06	1.31e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—muscle cancer	1.4e-06	1.28e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—muscle cancer	1.29e-06	1.18e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—muscle cancer	1.22e-06	1.12e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—muscle cancer	1.08e-06	9.93e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—muscle cancer	7.92e-07	7.28e-06	CbGpPWpGaD
